PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer
View Patent ↗The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
1. A method for treating a patient having pancreatic cancer by inhibiting the growth of a pancreatic cancer cell expressing the Prostate Stem Cell Antigen (PSCA) protein as shown in SEQ ID NO: 2 in the patient, comprising contacting the pancreatic cancer cell with the monoclonal antibody 1G8 (ATCC No. HB-12612), or a fragment thereof that recognizes and binds PSCA as shown in SEQ ID NO:2; an immunoconjugate of the antibody; or the fragment linked to a therapeutic agent; a humanized form of the 1G8 monoclonal antibody; or a fusion protein comprising the fragment of the 1G8 monoclonal antibody in an amount effective to inhibit the growth of the pancreatic cancer cell.
2. A method of claim 1 wherein the pancreatic cancer cell is killed.
3. The method of claim 1 , wherein the contacting is with the 1GS monclonal antibody or the fragmentthat recognizes and binds the PSCA as shown in SEQ ID NO: 2.
4. The method of claim 3 , wherein the fragment is a Fab, F(ab′) 2 , or Fv fragment.
5. The method of claim 1 , wherein the contacting is with the fusion protein.
6. The method of claim 1 , wherein the contacting is with the humanized form of the 1G8 monoclonal antibody.
7. The method of claim 1 , wherein the contacting is with the immunoconjugate linked to a therapeutic agent.
8. The method of claim 7 , wherein the therapeutic agent is a cytotoxic agent.
9. The method of claim 7 , wherein the therapeutic agent is a radioactive isotope.
10. The method of claim 1 further comprising administering to the patient a chemotherapeutic drug.
11. The method of claim 1 further comprising administering radiation therapy to the patient.
12. The method of claim 1 , wherein the contacting comprises administering the antibody directly into a pancreatic cancer, or a metastasis of pancreatic cancer.